Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients
•Non-response to inactivated and recombinant vaccines is similar among healthy controls (8%), non-cirrhosis CLD patients (16%), and compensated cirrhosis patients (17%).•Cellular immunity was similar among healthy controls, NCCLD, and compensated cirrhosis groups.•Approximately 34% and 59% of decomp...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2022-11, Vol.40 (48), p.6971-6978 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6978 |
|---|---|
| container_issue | 48 |
| container_start_page | 6971 |
| container_title | Vaccine |
| container_volume | 40 |
| creator | Kulkarni, Anand V. Jaggaiahgari, Shashidhar Iyengar, Sowmya Simhadri, Venu Gujjarlapudi, Deepika Rugwani, Hardik Vemula, Venkata Krishna Gora, Baqar Ali Shaik, Sameer Sharma, Mithun Sasikala, Mitnal Padaki, Nagaraja Rao Rajender Reddy, K. Reddy, Duvvur Nageshwar |
| description | •Non-response to inactivated and recombinant vaccines is similar among healthy controls (8%), non-cirrhosis CLD patients (16%), and compensated cirrhosis patients (17%).•Cellular immunity was similar among healthy controls, NCCLD, and compensated cirrhosis groups.•Approximately 34% and 59% of decompensated cirrhosis patients and liver transplant recipients were non-responders.•Decompensated cirrhosis and liver transplant recipients demonstrated poor humoral (lower antibody levels) and cellular response.
Recent studies have reported poor humoral immune response to mRNA vaccines in patients with chronic liver disease (CLD). However, the immunogenicity of ChAdOx1 (vector-based) and BBV152 (inactivated virus) vaccines in patients with CLD and liver transplant recipients (LTRs) is unknown. Therefore, we aimed to assess the immunogenicity of ChAdOx1 and BBV152 vaccines in patients with CLD (including cirrhosis patients) and LTRs.
In this single-center prospective study, consecutive completely vaccinated (ChAdOx1 or BBV152) non-cirrhosis CLD patients, those with cirrhosis, and LTRs were compared with matched healthy controls for anti-spike antibody and cellular response.
Sixty healthy individuals, 50 NCCLD patients, 63 compensated and 50 decompensated cirrhosis, and 17 LTRs were included. The proportion of non-responders was similar among the healthy control (8 %), non-cirrhosis CLD (16 %), and compensated cirrhosis groups (17.5 %;p = 0.3). However, a higher proportion of patients with decompensated cirrhosis (34 %) and LTRs (59 %) were non-responders than the healthy controls (p = 0.001). Cluster of differentiation (CD) 4-effector cells were lower in patients with non-cirrhosis CLD and compensated cirrhosis. CD4-naïve, CD4-effector, B, and B-memory cells were lower in the decompensated cirrhosis group. Although the central memory cells were higher in the decompensated cirrhosis group, they could not differentiate into effector cells. CD4- and CD8-naïve cells were higher in the marrow in the LTRs, while the CD4-effector memory cells and CD4- and CD8-effector cells were lower in the LTRs. Furthermore, B cells were more deficient in the LTRs, suggesting poor antibody response.
Patients with decompensated cirrhosis and LTRs demonstrated suboptimal humoral and cellular immune responses against recombinant and inactivated COVID-19 vaccines. |
| doi_str_mv | 10.1016/j.vaccine.2022.10.042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9595300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X22013020</els_id><sourcerecordid>2734072613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-33021e447a825de6f28090ae4ed6faa1a54e92dc7944b2f9f1596ef92a2fff973</originalsourceid><addsrcrecordid>eNqFkk2LFDEQhoMo7rj6E5SAFy895rPTuSjL4hcs6EHBW8gmFTfDdNIm3Y3-ezPOuKiXJYdA1ZN6U_UWQk8p2VJC-5e77Wqdiwm2jDDWYlsi2D20oYPiHZN0uI82hPWiE5R8PUOPat0RQiSn-iE64z1XQhG1QT8-5VxwHMclAS5Qp5wq4Dljl0tOdo1lqdjHCraFT4oVx4Q9uDxOkKqdwWMXS7nJNVY82TlCmiu2yeN9XKHgudhUp71Nc1Nwcfqdf4weBLuv8OR0n6Mvb998vnzfXX189-Hy4qpzkg1zxzlhFIRQdmDSQx_YQDSxIMD3wVpqpQDNvFNaiGsWdKBS9xA0syyEoBU_R6-OdaflegTvmnaxezOVONry02Qbzb-ZFG_Mt7waLbXkhLQCL04FSv6-QJ3NGKuDfesH8lINp5IPrB11J8pUGzzhzZGGPv8P3eWlpDaJAyWIYj3ljZJHypVca4Fw-29KzGENzM6cTDGHNTiE2xq0d8_-bvr21R_fG_D6CEAb_RqhmOqaLQ58bBbNxud4h8Qvbf_J2g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2734072613</pqid></control><display><type>article</type><title>Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kulkarni, Anand V. ; Jaggaiahgari, Shashidhar ; Iyengar, Sowmya ; Simhadri, Venu ; Gujjarlapudi, Deepika ; Rugwani, Hardik ; Vemula, Venkata Krishna ; Gora, Baqar Ali ; Shaik, Sameer ; Sharma, Mithun ; Sasikala, Mitnal ; Padaki, Nagaraja Rao ; Rajender Reddy, K. ; Reddy, Duvvur Nageshwar</creator><creatorcontrib>Kulkarni, Anand V. ; Jaggaiahgari, Shashidhar ; Iyengar, Sowmya ; Simhadri, Venu ; Gujjarlapudi, Deepika ; Rugwani, Hardik ; Vemula, Venkata Krishna ; Gora, Baqar Ali ; Shaik, Sameer ; Sharma, Mithun ; Sasikala, Mitnal ; Padaki, Nagaraja Rao ; Rajender Reddy, K. ; Reddy, Duvvur Nageshwar</creatorcontrib><description>•Non-response to inactivated and recombinant vaccines is similar among healthy controls (8%), non-cirrhosis CLD patients (16%), and compensated cirrhosis patients (17%).•Cellular immunity was similar among healthy controls, NCCLD, and compensated cirrhosis groups.•Approximately 34% and 59% of decompensated cirrhosis patients and liver transplant recipients were non-responders.•Decompensated cirrhosis and liver transplant recipients demonstrated poor humoral (lower antibody levels) and cellular response.
Recent studies have reported poor humoral immune response to mRNA vaccines in patients with chronic liver disease (CLD). However, the immunogenicity of ChAdOx1 (vector-based) and BBV152 (inactivated virus) vaccines in patients with CLD and liver transplant recipients (LTRs) is unknown. Therefore, we aimed to assess the immunogenicity of ChAdOx1 and BBV152 vaccines in patients with CLD (including cirrhosis patients) and LTRs.
In this single-center prospective study, consecutive completely vaccinated (ChAdOx1 or BBV152) non-cirrhosis CLD patients, those with cirrhosis, and LTRs were compared with matched healthy controls for anti-spike antibody and cellular response.
Sixty healthy individuals, 50 NCCLD patients, 63 compensated and 50 decompensated cirrhosis, and 17 LTRs were included. The proportion of non-responders was similar among the healthy control (8 %), non-cirrhosis CLD (16 %), and compensated cirrhosis groups (17.5 %;p = 0.3). However, a higher proportion of patients with decompensated cirrhosis (34 %) and LTRs (59 %) were non-responders than the healthy controls (p = 0.001). Cluster of differentiation (CD) 4-effector cells were lower in patients with non-cirrhosis CLD and compensated cirrhosis. CD4-naïve, CD4-effector, B, and B-memory cells were lower in the decompensated cirrhosis group. Although the central memory cells were higher in the decompensated cirrhosis group, they could not differentiate into effector cells. CD4- and CD8-naïve cells were higher in the marrow in the LTRs, while the CD4-effector memory cells and CD4- and CD8-effector cells were lower in the LTRs. Furthermore, B cells were more deficient in the LTRs, suggesting poor antibody response.
Patients with decompensated cirrhosis and LTRs demonstrated suboptimal humoral and cellular immune responses against recombinant and inactivated COVID-19 vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2022.10.042</identifier><identifier>PMID: 36374707</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Antibodies ; Antibody formation ; Antibody response ; Cardiovascular disease ; CD4 antigen ; CD8 antigen ; Cell differentiation ; Cellular immunity ; Cirrhosis ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 infection ; COVID-19 Vaccines ; Creatinine ; Deactivation ; Diabetes ; Effector cells ; Flow cytometry ; Hepatitis ; Histology ; Humans ; Humoral immunity ; Immune response ; Immune response (cell-mediated) ; Immune response (humoral) ; Immune system ; Immunity ; Immunogenicity ; Infections ; Liver ; Liver Cirrhosis ; Liver Diseases ; liver transplant ; Liver Transplantation ; Liver transplants ; Lymphocytes ; Lymphocytes B ; memory ; Memory cells ; mRNA ; Patients ; Prospective Studies ; Severe acute respiratory syndrome coronavirus 2 ; Transplant Recipients ; Vaccines ; Variance analysis ; Viral diseases ; viruses</subject><ispartof>Vaccine, 2022-11, Vol.40 (48), p.6971-6978</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><rights>2022. Elsevier Ltd</rights><rights>2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-33021e447a825de6f28090ae4ed6faa1a54e92dc7944b2f9f1596ef92a2fff973</citedby><cites>FETCH-LOGICAL-c528t-33021e447a825de6f28090ae4ed6faa1a54e92dc7944b2f9f1596ef92a2fff973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X22013020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36374707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kulkarni, Anand V.</creatorcontrib><creatorcontrib>Jaggaiahgari, Shashidhar</creatorcontrib><creatorcontrib>Iyengar, Sowmya</creatorcontrib><creatorcontrib>Simhadri, Venu</creatorcontrib><creatorcontrib>Gujjarlapudi, Deepika</creatorcontrib><creatorcontrib>Rugwani, Hardik</creatorcontrib><creatorcontrib>Vemula, Venkata Krishna</creatorcontrib><creatorcontrib>Gora, Baqar Ali</creatorcontrib><creatorcontrib>Shaik, Sameer</creatorcontrib><creatorcontrib>Sharma, Mithun</creatorcontrib><creatorcontrib>Sasikala, Mitnal</creatorcontrib><creatorcontrib>Padaki, Nagaraja Rao</creatorcontrib><creatorcontrib>Rajender Reddy, K.</creatorcontrib><creatorcontrib>Reddy, Duvvur Nageshwar</creatorcontrib><title>Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Non-response to inactivated and recombinant vaccines is similar among healthy controls (8%), non-cirrhosis CLD patients (16%), and compensated cirrhosis patients (17%).•Cellular immunity was similar among healthy controls, NCCLD, and compensated cirrhosis groups.•Approximately 34% and 59% of decompensated cirrhosis patients and liver transplant recipients were non-responders.•Decompensated cirrhosis and liver transplant recipients demonstrated poor humoral (lower antibody levels) and cellular response.
Recent studies have reported poor humoral immune response to mRNA vaccines in patients with chronic liver disease (CLD). However, the immunogenicity of ChAdOx1 (vector-based) and BBV152 (inactivated virus) vaccines in patients with CLD and liver transplant recipients (LTRs) is unknown. Therefore, we aimed to assess the immunogenicity of ChAdOx1 and BBV152 vaccines in patients with CLD (including cirrhosis patients) and LTRs.
In this single-center prospective study, consecutive completely vaccinated (ChAdOx1 or BBV152) non-cirrhosis CLD patients, those with cirrhosis, and LTRs were compared with matched healthy controls for anti-spike antibody and cellular response.
Sixty healthy individuals, 50 NCCLD patients, 63 compensated and 50 decompensated cirrhosis, and 17 LTRs were included. The proportion of non-responders was similar among the healthy control (8 %), non-cirrhosis CLD (16 %), and compensated cirrhosis groups (17.5 %;p = 0.3). However, a higher proportion of patients with decompensated cirrhosis (34 %) and LTRs (59 %) were non-responders than the healthy controls (p = 0.001). Cluster of differentiation (CD) 4-effector cells were lower in patients with non-cirrhosis CLD and compensated cirrhosis. CD4-naïve, CD4-effector, B, and B-memory cells were lower in the decompensated cirrhosis group. Although the central memory cells were higher in the decompensated cirrhosis group, they could not differentiate into effector cells. CD4- and CD8-naïve cells were higher in the marrow in the LTRs, while the CD4-effector memory cells and CD4- and CD8-effector cells were lower in the LTRs. Furthermore, B cells were more deficient in the LTRs, suggesting poor antibody response.
Patients with decompensated cirrhosis and LTRs demonstrated suboptimal humoral and cellular immune responses against recombinant and inactivated COVID-19 vaccines.</description><subject>Antibodies</subject><subject>Antibody formation</subject><subject>Antibody response</subject><subject>Cardiovascular disease</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Cell differentiation</subject><subject>Cellular immunity</subject><subject>Cirrhosis</subject><subject>Coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 infection</subject><subject>COVID-19 Vaccines</subject><subject>Creatinine</subject><subject>Deactivation</subject><subject>Diabetes</subject><subject>Effector cells</subject><subject>Flow cytometry</subject><subject>Hepatitis</subject><subject>Histology</subject><subject>Humans</subject><subject>Humoral immunity</subject><subject>Immune response</subject><subject>Immune response (cell-mediated)</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>Immunity</subject><subject>Immunogenicity</subject><subject>Infections</subject><subject>Liver</subject><subject>Liver Cirrhosis</subject><subject>Liver Diseases</subject><subject>liver transplant</subject><subject>Liver Transplantation</subject><subject>Liver transplants</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>memory</subject><subject>Memory cells</subject><subject>mRNA</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Transplant Recipients</subject><subject>Vaccines</subject><subject>Variance analysis</subject><subject>Viral diseases</subject><subject>viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk2LFDEQhoMo7rj6E5SAFy895rPTuSjL4hcs6EHBW8gmFTfDdNIm3Y3-ezPOuKiXJYdA1ZN6U_UWQk8p2VJC-5e77Wqdiwm2jDDWYlsi2D20oYPiHZN0uI82hPWiE5R8PUOPat0RQiSn-iE64z1XQhG1QT8-5VxwHMclAS5Qp5wq4Dljl0tOdo1lqdjHCraFT4oVx4Q9uDxOkKqdwWMXS7nJNVY82TlCmiu2yeN9XKHgudhUp71Nc1Nwcfqdf4weBLuv8OR0n6Mvb998vnzfXX189-Hy4qpzkg1zxzlhFIRQdmDSQx_YQDSxIMD3wVpqpQDNvFNaiGsWdKBS9xA0syyEoBU_R6-OdaflegTvmnaxezOVONry02Qbzb-ZFG_Mt7waLbXkhLQCL04FSv6-QJ3NGKuDfesH8lINp5IPrB11J8pUGzzhzZGGPv8P3eWlpDaJAyWIYj3ljZJHypVca4Fw-29KzGENzM6cTDGHNTiE2xq0d8_-bvr21R_fG_D6CEAb_RqhmOqaLQ58bBbNxud4h8Qvbf_J2g</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Kulkarni, Anand V.</creator><creator>Jaggaiahgari, Shashidhar</creator><creator>Iyengar, Sowmya</creator><creator>Simhadri, Venu</creator><creator>Gujjarlapudi, Deepika</creator><creator>Rugwani, Hardik</creator><creator>Vemula, Venkata Krishna</creator><creator>Gora, Baqar Ali</creator><creator>Shaik, Sameer</creator><creator>Sharma, Mithun</creator><creator>Sasikala, Mitnal</creator><creator>Padaki, Nagaraja Rao</creator><creator>Rajender Reddy, K.</creator><creator>Reddy, Duvvur Nageshwar</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20221115</creationdate><title>Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients</title><author>Kulkarni, Anand V. ; Jaggaiahgari, Shashidhar ; Iyengar, Sowmya ; Simhadri, Venu ; Gujjarlapudi, Deepika ; Rugwani, Hardik ; Vemula, Venkata Krishna ; Gora, Baqar Ali ; Shaik, Sameer ; Sharma, Mithun ; Sasikala, Mitnal ; Padaki, Nagaraja Rao ; Rajender Reddy, K. ; Reddy, Duvvur Nageshwar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-33021e447a825de6f28090ae4ed6faa1a54e92dc7944b2f9f1596ef92a2fff973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Antibody formation</topic><topic>Antibody response</topic><topic>Cardiovascular disease</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Cell differentiation</topic><topic>Cellular immunity</topic><topic>Cirrhosis</topic><topic>Coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 infection</topic><topic>COVID-19 Vaccines</topic><topic>Creatinine</topic><topic>Deactivation</topic><topic>Diabetes</topic><topic>Effector cells</topic><topic>Flow cytometry</topic><topic>Hepatitis</topic><topic>Histology</topic><topic>Humans</topic><topic>Humoral immunity</topic><topic>Immune response</topic><topic>Immune response (cell-mediated)</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>Immunity</topic><topic>Immunogenicity</topic><topic>Infections</topic><topic>Liver</topic><topic>Liver Cirrhosis</topic><topic>Liver Diseases</topic><topic>liver transplant</topic><topic>Liver Transplantation</topic><topic>Liver transplants</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>memory</topic><topic>Memory cells</topic><topic>mRNA</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Transplant Recipients</topic><topic>Vaccines</topic><topic>Variance analysis</topic><topic>Viral diseases</topic><topic>viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kulkarni, Anand V.</creatorcontrib><creatorcontrib>Jaggaiahgari, Shashidhar</creatorcontrib><creatorcontrib>Iyengar, Sowmya</creatorcontrib><creatorcontrib>Simhadri, Venu</creatorcontrib><creatorcontrib>Gujjarlapudi, Deepika</creatorcontrib><creatorcontrib>Rugwani, Hardik</creatorcontrib><creatorcontrib>Vemula, Venkata Krishna</creatorcontrib><creatorcontrib>Gora, Baqar Ali</creatorcontrib><creatorcontrib>Shaik, Sameer</creatorcontrib><creatorcontrib>Sharma, Mithun</creatorcontrib><creatorcontrib>Sasikala, Mitnal</creatorcontrib><creatorcontrib>Padaki, Nagaraja Rao</creatorcontrib><creatorcontrib>Rajender Reddy, K.</creatorcontrib><creatorcontrib>Reddy, Duvvur Nageshwar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kulkarni, Anand V.</au><au>Jaggaiahgari, Shashidhar</au><au>Iyengar, Sowmya</au><au>Simhadri, Venu</au><au>Gujjarlapudi, Deepika</au><au>Rugwani, Hardik</au><au>Vemula, Venkata Krishna</au><au>Gora, Baqar Ali</au><au>Shaik, Sameer</au><au>Sharma, Mithun</au><au>Sasikala, Mitnal</au><au>Padaki, Nagaraja Rao</au><au>Rajender Reddy, K.</au><au>Reddy, Duvvur Nageshwar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2022-11-15</date><risdate>2022</risdate><volume>40</volume><issue>48</issue><spage>6971</spage><epage>6978</epage><pages>6971-6978</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Non-response to inactivated and recombinant vaccines is similar among healthy controls (8%), non-cirrhosis CLD patients (16%), and compensated cirrhosis patients (17%).•Cellular immunity was similar among healthy controls, NCCLD, and compensated cirrhosis groups.•Approximately 34% and 59% of decompensated cirrhosis patients and liver transplant recipients were non-responders.•Decompensated cirrhosis and liver transplant recipients demonstrated poor humoral (lower antibody levels) and cellular response.
Recent studies have reported poor humoral immune response to mRNA vaccines in patients with chronic liver disease (CLD). However, the immunogenicity of ChAdOx1 (vector-based) and BBV152 (inactivated virus) vaccines in patients with CLD and liver transplant recipients (LTRs) is unknown. Therefore, we aimed to assess the immunogenicity of ChAdOx1 and BBV152 vaccines in patients with CLD (including cirrhosis patients) and LTRs.
In this single-center prospective study, consecutive completely vaccinated (ChAdOx1 or BBV152) non-cirrhosis CLD patients, those with cirrhosis, and LTRs were compared with matched healthy controls for anti-spike antibody and cellular response.
Sixty healthy individuals, 50 NCCLD patients, 63 compensated and 50 decompensated cirrhosis, and 17 LTRs were included. The proportion of non-responders was similar among the healthy control (8 %), non-cirrhosis CLD (16 %), and compensated cirrhosis groups (17.5 %;p = 0.3). However, a higher proportion of patients with decompensated cirrhosis (34 %) and LTRs (59 %) were non-responders than the healthy controls (p = 0.001). Cluster of differentiation (CD) 4-effector cells were lower in patients with non-cirrhosis CLD and compensated cirrhosis. CD4-naïve, CD4-effector, B, and B-memory cells were lower in the decompensated cirrhosis group. Although the central memory cells were higher in the decompensated cirrhosis group, they could not differentiate into effector cells. CD4- and CD8-naïve cells were higher in the marrow in the LTRs, while the CD4-effector memory cells and CD4- and CD8-effector cells were lower in the LTRs. Furthermore, B cells were more deficient in the LTRs, suggesting poor antibody response.
Patients with decompensated cirrhosis and LTRs demonstrated suboptimal humoral and cellular immune responses against recombinant and inactivated COVID-19 vaccines.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>36374707</pmid><doi>10.1016/j.vaccine.2022.10.042</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2022-11, Vol.40 (48), p.6971-6978 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9595300 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies Antibody formation Antibody response Cardiovascular disease CD4 antigen CD8 antigen Cell differentiation Cellular immunity Cirrhosis Coronavirus Coronaviruses COVID-19 COVID-19 infection COVID-19 Vaccines Creatinine Deactivation Diabetes Effector cells Flow cytometry Hepatitis Histology Humans Humoral immunity Immune response Immune response (cell-mediated) Immune response (humoral) Immune system Immunity Immunogenicity Infections Liver Liver Cirrhosis Liver Diseases liver transplant Liver Transplantation Liver transplants Lymphocytes Lymphocytes B memory Memory cells mRNA Patients Prospective Studies Severe acute respiratory syndrome coronavirus 2 Transplant Recipients Vaccines Variance analysis Viral diseases viruses |
| title | Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A28%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poor%20immune%20response%20to%20coronavirus%20disease%20vaccines%20in%20decompensated%20cirrhosis%20patients%20and%20liver%20transplant%20recipients&rft.jtitle=Vaccine&rft.au=Kulkarni,%20Anand%20V.&rft.date=2022-11-15&rft.volume=40&rft.issue=48&rft.spage=6971&rft.epage=6978&rft.pages=6971-6978&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2022.10.042&rft_dat=%3Cproquest_pubme%3E2734072613%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2734072613&rft_id=info:pmid/36374707&rft_els_id=S0264410X22013020&rfr_iscdi=true |